Pyxis Oncology (PYXS) Gross Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Gross Margin of 78.37% for Q4 2025, down 21.63% quarter-over-quarter from 100.0% in Q2 2025.

Pyxis Oncology (PYXS) Gross Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Gross Margin for 2 consecutive years, with 78.37% the latest figure, recorded in Q4 2025.

In Q4 2025, Gross Margin changed N/A year-over-year to 78.37%; the TTM figure through Dec 2025 stood at 82.77% (down 1429.0% YoY), while the FY2025 annual figure was 82.77%, down 1429.0% from the prior year.
Gross Margin slipped to 78.37% in Q4 2025 per PYXS's latest filing, from 100.0% in the prior quarter.
Across five years, Gross Margin topped out at 100.0% in Q2 2025 and bottomed at 78.37% in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Gross Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	85.33%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	91.59%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	90.43%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	35.86%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	89.76%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	76.90%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	84.20%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	63.27%
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data